Sixteen leaders from key federal, academic and industry organizations have been appointed by Governor Larry Hogan to the Maryland Life Sciences Advisory Board (LSAB).
The new appointees include a patient advocate, executives from global life sciences companies with U.S. headquarters in Maryland, small biotechnology companies, and leaders from the University of Maryland, University of Maryland Baltimore, Johns Hopkin University, Montgomery College, NIH, FDA and the U.S. Army Medical Research and Material Command.
We are very excited to welcome Andrea Custead, Yesenia Estrada and Tracy King to the BHI team!
Andrea Custead joined BHI at the beginning of 2016 as a Paralegal. She was hired as part of a collaborative arrangement between BHI and In House Patent Counsel (IHPC), a law firm which subleases office space from BHI. As part of this arrangement, Andrea splits her time between the two entities. Her time with BHI is spent both initiating and maintaining the organization’s legal correspondence related to its portfolio companies. Andrea brings over 25 years of legal experience to BHI. Andrea is a native of Montgomery County, Maryland and has been living in Frederick, Maryland for 20 years. She enjoys spending time with her husband and children and their Rat Terrier, Lexi.
Yesenia Estrada is the Operations Administrator at BHI. In this role she supports the HR & Finance Director as well as the EIR and Relevant Health programs. Yesenia brings with her over seven years of administrative experience and over the last four years
Yesenia Estrada expanded her expertise to include performing accounting functions as well as HR administrative work at Intelligent Office in Rockville, MD and Columbia Books & Information Services in Bethesda, MD. Yesenia is a native of Montgomery County and loves her home state of Maryland. She is a Maryland Terrapin and an avid Baltimore Ravens fan. She enjoys cooking, traveling, and spending time with her family, friends, and fiancé Michael.
Ligand Pharmaceuticals enters into a global license agreement with Emergent BioSolutions under which Emergent will use Ligand’s OmniRat, OmniMouse and OmniFlic technologies to discover fully human mono- and bispecific antibodies.
In a partnership announced today, MedImmune, AstraZeneca’s global biologics and development arm, and the University of California, San Francisco will initiate further exploration of disease biology, specifically delving into core underlying mechanisms in microbiome and regenerative medicine. With an emphasis on basic research and translational sciences, the organizations’ work will include working toward identifying biomarkers and understanding disease progression and the effects of biomarkers on clinical trial outcomes.
NEW YORK (GenomeWeb) – Qiagen said yesterday that it has inked a master collaboration for companion diagnostics codevelopment with Array BioPharma, the 15th pharma agreement of this type.
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.
Last year, three biomedical engineering (BME) MS students—Teresa Cauvel, Rebecca Peyser, and Sona Shah—took BME Lecturer Katherine E. Reuther’s new design course and came up with an idea for a health technology startup they called Neopenda. Their concept, born in January and shaped through Reuther’s class over the spring semester, was a low-cost, low-power, low-maintenance way to monitor neonatal vitals through engineered “hats,” a headband containing a small circuit that measures heart rate, respiratory rate, temperature, and blood oxygen saturation in critically ill infants and then sends the data to a centralized monitoring device.
Venture capitalists invested a whopping $451 million in Maryland companies in the last three months of 2015, the largest quarterly amount in the state in 15 years.
“We have released our annual Regional Report. The report benchmarks the region against other metropolitan regions, the national average and specifically markets comparable to the Greater Baltimore region. This year’s report analyzes the region’s employment, innovation, quality of life, jobs and investment.”
Washington-area businesses raised more venture capital in the fourth quarter than they had in any quarter since 2001 — largely due to a few large deals.
The surge is not likely to be repeated soon given the recent stock market turmoil. Indeed, venture funding nationally declined during the period.
What’s the difference between a relatively flat economy and a vibrant and diversified region with high job and economic growth? Working together. That was the pitch Thursday morning as economist Steve Fuller unveiled the findings after months of research for a project dubbed “ The Roadmap for the Washington Region’s Economic Future.”
You’ve heard of 3-D printers creating architectural models, airplane parts and even prosthetic limbs. But bones? Warren Grayson, an assistant professor of biomedical engineering at Johns Hopkins University, says it’s possible and not so far off in the future.
TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.
Our livers rested, our business cards sheathed – one more year of the J.P. Morgan Healthcare Conference has come and gone. Given that the week was relatively quiet in terms of breaking news, the focus rested more solidly on trend analysis, moodiness – and what was not said. It also showed undercurrents of change.
It’s been a frenetic couple of weeks between Consumer Electronics Show and J.P. Morgan Healthcare conference so now it’s time to take a broader look at what investors took away from them. The latter conference has certainly evolved since its start as Hambrecht & Quist.
ATCC, the premier global biological materials resource and standards organization, announces today that it licensed CRISPR/Cas9 gene editing technology from the Broad Institute of MIT and Harvard. ATCC plans to use the gene editing technology to develop a portfolio of new products and services to support basic and translational research.
AUTM today released its highly regarded annual U.S. Licensing Activity Survey report for FY2014. Along with real world and human impact stories about technology transfer’s ability to improve lives and boost economies, the report analyzes licensing activities at U.S. universities, hospitals and research institutions, with data such as the following:
The way Health and Human Services Chief Technology Officer Susannah Fox sees it, the U.S. government totally missed the Internet boom and has been trying to catch up with ever since.
“I would say gently that the government was caught flat footed when the Internet came about,” she said
Advanced Accelerator Applications S.A. (NASDAQ: AAAP) announced an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes. AAA will focus on developing this treatment and its companion diagnostic for prostate cancer through novel molecular nuclear medicine techniques similar to those implemented for the development of Lutathera and Somakit. Prostate cancer affects nearly 1 in 7 men during their lifetime worldwide.
Leading global start up accelerator Dreamit today announced that it has renewed its partnerships with industry leaders Independence Blue Cross (Independence) and Penn Medicine to advance entrepreneurship and innovation in health care. The continued support follows significant upgrades to the Dreamit Health program announced earlier this year. The new model includes key changes designed to appeal to a broader range of entrepreneurs, including a no-cash/no-equity offer to draw later-stage companies and serial entrepreneurs who would not typically consider an accelerator program.
Biological researchers should be able to share datasets the same way they share published scientific articles — at least, that’s what the National Institutes of Health is trying to ensure with a new project.
NIH is building a virtual space called “the Commons,” where researchers can one day do just that: share data, software and any other virtual tools or research processes in a way that’s “Findable, Accessible, Interoperable and Reusable,” or “FAIR.”
The American Medical Association has invested $15 million to become founding partner of Health2047, a high-tech incubator that will explore innovative solutions to some of the biggest challenges facing the nation’s 1.1 million physicians and their patients.
Thursday January 21, 2016 from 5:00 PM to 7:00 PM EST
Johns Hopkins Montgomery County Campus is also a site for the popular Osher Lifelong Learning Institute. Geared toward retirees, these non-credit classes cover topics including opera, literature, history, politics and more.
The campus is home to approximately 35 research companies and entrepreneurs. Scientists on campus are studying cervical cancer, Alzheimer’s disease, cell therapy, proteins and other health issues. Other companies focus on technology, medical devices and consulting services. The Rockville Science Center’s administrative offices are located here. Start-up companies, second-stage businesses and more established companies are welcome.
Germany has a long-standing reputation for life science innovation. However, most pharmaceutical and biotech companies are now headquartered in the US, and significantly more digital health solutions are developed in Silicon Valley and Boston than in Berlin or Munich.
At its recent AgeTech Expo, Aging2.0 held the 3rd annual Pitch-for-Pilots (P4P) competition where market-ready startups pitched their innovations to senior care providers in the audience in hopes of securing pilot partnerships. Selected from more than 150 applications, the pitching companies presented the challenge they are addressing, their solution, what kind of pilot they would like to run and any requirements for the potential provider partner. The prize at hand for senior care partners? A free, 6-week pilot with at least 10 senior participants.
Hundreds of people packed into Morgan State University’s Murphy Fine Arts Center on Thursday for this year’s TEDxBaltimore. FEATURED JOBS Design Assistant / Project Manager C.N.Robinson
Entry Level Management Trainee – Marketing / Sales / PR GVG, Inc. Med Tech/CNA/Caregiver Brightview Senior Living Post a JobSee More Jobs The day-long event featured 15-minute talks from 17 speakers on topics ranging from scientific discovery and space exploration to prison reform and racial inequality. There were too many interesting ideas to talk about them all, but here are a few that captured my attention:
This position is located in the Office of Technology Transitions and reports directly to the Director, Office of Technology Transitions. If selected for this position, you will manage the OTT staff, as the advisor to the Director, and provide continuity between administrations. The Deputy Director will be a senior level staff serving as a point of contact for entities like the Laboratory Operations (LOB), Laboratory Policy Council (LPC), and Secretary’s External Advisory Board (SEAB). The Deputy Director will manage the intra-agency tech Transfer Policy Board (TTPB). The Deputy Director will serves as an integral part of the Office of Technology Transitions, overseeing the day-today operations of the Office, continuously seeking efficiencies by providing oversight and coordination. The Deputy Director will develop and manage fit-for purpose oversight processed and procedures for technology transfer and reporting systems, including intellectual property, across the DOE enterprise. The Deputy Director will lead the development of annual OTT deliverables, working with appropriate DOE programmatic elements. The Deputy Director will lead OTT staff to ensure delivery of state of the art data management processes and solutions supporting effective technology transitions and outreach to the private sector. The Deputy Director will lead interactions needed with the Executive Office of the White House, the Office of Management and Budget (OMB), the General Services Administration (GSA), Congressional Committees and Subcommittees, State Officials, the non-profit sector, and other non-commercial entities to ensure DOE technology transitions polices and priorities are appropriately linked with related initiatives, and to improve existing, or develop new, processes and procedures for supporting technology transfer solutions.
The Obama administration has launched a ‘moonshot’ initiative to cure cancer that will involve increasing resources – both private and public – to fight cancer and break down walls between disciplines in the oncology arena. The effort will be led by vice president Joe Biden, who lost his son to brain cancer last year, President Obama announced during his final State of the Union speech. Biden worked with Congress last month to provide the US National Institutes of Health with its strongest budget in over a decade, Obama noted. ‘Let’s make America the country that cures cancer once and for all,’ he added.
The TCM Industry Awards Celebration is the only awards ceremony that honors the best in Maryland’s technology and life science communities and is one of Maryland’s largest and most prestigious award ceremonies.
Awards go to those who develop the treatments, design the systems, and teach the children. It’s a celebration of great minds and the companies that believe in the future, and is attended by over 800 executives from the technology and life science industries, drawing a significant amount of local and national publicity.
GE Healthcare, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), and the Centre for Commercialization of Regenerative Medicine (CCRM) are building a centre for advanced therapeutic cell technologies in Toronto with an investment of CAD $40M from GE and FedDev Ontario. The centre is being established to accelerate the development and adoption of cell manufacturing technologies that improve patient access to novel regenerative medicine-based therapies. CCRM and GE will welcome partners from pharma, biotech and cell therapy companies to bring this initiative to life.
The information contained in this website and newsletters is for general information purposes only. The information is provided by BioHealth Innovation via its newsletters, but not written or endorsed in any way by BioHealth Innovation unless otherwise noted. While we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
